Clinical Trials Browser

Phase 2 × NIH × Epoetin Alfa × Clear all

NCT05564390 2026-03-18

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Phase 2 Recruiting

2,000 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Phase 2 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative